Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: A post hoc, pooled analysis from two placebo-controlled trials
Neurourology and Urodynamics, 08/21/2012
Clinical Article
DuBeau CE et al. – Fesoterodine 8 mg consistently improved several overactive bladder–related variables versus tolterodine extended release 4 mg in subjects aged <65, 65–74, and ≥75 years, with some differences reaching statistical significance, and was generally well tolerated.



